Treatment Of Recurrent Oral Ulcers Research Articles

Clinical efficacy of recombinant human basic fibroblast growth factor combined with ranitidine in the treatment of recurrent oral ulcer and its effect on serum TNF, IL-2 and T-lymphocyte subsets.

To evaluate the clinical efficacy of recombinant human basic fibroblast growth factor (rh-bFGF) combined with ranitidine in the treatment of recurrent oral ulcer and its effects on serum TNF, IL-2 and T-lymphocyte subsets. This was a retrospective study. Eighty patients with oral ulcers admitted to First Medical Center, Chinese PLA General Hospital from July 2021 to June 2022 were randomly divided into the control group and the experimental group (n=40). Patients in the control group were given topical treatment with rh-bFGF gel, while those in the experimental group were given oral treatment combined with ranitidine based on the control group, and both groups were treated continuously for 14 days. The therapeutic effect, pain relief time, ulcer healing time, as well as the differences in the levels of inflammatory factors and T-lymphocyte subsets were compared and analyzed between the two groups. The overall response rate of the experimental group was 92.5%, while that of the control group was 75%, with a statistically significant difference(P=0.03). After treatment, inflammatory factors indexes in the experimental group were significantly lower than those in the control group, with statistically significant differences (P=0.00). The indexes of T-lymphocyte subsets in the experimental group were significantly higher than those in the control group after treatment, with statistically significant differences (P=0.00). Recombinant human basic fibroblast growth factor combined with ranitidine is effective in the treatment of recurrent oral ulcers, boasting various benefits such as effectively promoting ulcer healing, reducing pain and inflammatory response, and enhancing immune function.

Effect of intradermal acupuncture combined with auricular acupoint pressing in the treatment of recurrent oral ulcers

Effect of intradermal acupuncture combined with auricular acupoint pressing in the treatment of recurrent oral ulcers

Evaluation of the Efficacy and Performance of a New Nano-Drug Carrier in the Treatment of Recurrent Oral Ulcerper.

Recurrent oral ulcer is a common oral mucosal disease. Due to its periodic and recurrent characteristics, the onset of burning pain is unbearable, which brings great inconvenience to the patient's life and seriously affects the patient's quality of life. There are certain limitations to conventional drug therapy. With the rapid development of nanotechnology, the obvious advantages of nanotechnology such as targeting, controlled release, biocompatibility is obviously shown. The combination of nanotechnology and medical research has led to the emergence of polymer nanoparticles and ligands. Nano-drugs for gene therapy, and many other new nano-drug carriers, polymer micelle is a new type of nano drug carrier that has appeared in recent years. It has both a hydrophilic shell and a hydrophobic core, and has a variety of excellent properties, such as higher stability in vivo and in vitro, and poorly soluble drugs. In this paper, a new method for treating recurrent oral ulcers based on a new nano-drug carrier was studied. Because of the hydrophilicity and biocompatibility of oral cell surface proteins, the research progress of nanopharmaceutical carrier in the treatment of recurrent oral ulcers is reviewed. The experimental results show that the method has good reproducibility and high efficiency in the treatment of recurrent oral ulcers. It is used to explore the application and progress of nanotechnology in the diagnosis and treatment of recurrent oral ulcers, and to provide new ideas for the clinical diagnosis and treatment of recurrent oral ulcers. This new technical method has wide practical application value.

Comparative Evaluation of The Efficacy of Topical Hyaluronic Acid ( 0.2%) and Topical Triamcinolone Acetonide( 0.1%) in The Treatment of Recurrent Aphthous Stomatitis

Background: Recurrent aphthous ulcers are the most common oral lesion. They are classified into minor, major, and herpetiform ulcers. More than 85% of recurrent aphthous stomatitis presents as a minor ulcer. Hyaluronic acid is a biomaterial and it is a major carbohydrate component that can be found in many tissues and recently introduced as an alternative approach to enhance wound healing. Triamcinolone acetonide is a synthetic corticosteroid and it has two forms for topical use cream (0.1%) and ointment (0.1%). Objective: To make a comparison between the effectiveness of hyaluronic acid (0.2%) and triamcinolone acetonide (0.1) in the management of recurrent aphthous ulcer. Patients and Methods: We recruited eighty patients who had a history of recurrent aphthous stomatitis and when presented with current oral ulcer and randomly divided into two groups, one group received hyaluronic acid, and the other group received triamcinolone acetonide. The instruction was given to all patients to apply the agent to the aphthous ulcer 4 times per day for 6 days (day 0 to day 6). The severity of pain was assessed by using VAS and the change of the ulcer surface area measured. Results: Eighty patients with aphthous ulcers have participated in the study, 43 were treated with hyaluronic acid, 37 were treated with triamcinolone acetonide. There was a significant difference between the two groups regarding ulcer surface and after three and six days, the diameter of the ulcer in the hyaluronic acid group was significantly reduced in comparison with those of the triamcinolone acetonide group (p < 0.001). Regarding VAS for pain, there was a significant difference after three and six days, hyaluronic acid group had significantly less VAS than those of the triamcinolone acetonide group (p = 0.004 and p < 0.001 respectively). Conclusion: Hyaluronic acid is more effective than triamcinolone acetonide when used in the treatment of recurrent oral ulcers in reducing pain and surface area of the ulcer. Keywords: Hyaluronic acid (HA), Triamcinolone acetonide (TA), Recurrent aphthous stomatitis (RAS), comparative evaluation

Recurrent Oral Ulcers: current and future therapeutic approaches

Recurrent Oral Ulcers: current and future therapeutic approaches

Malakoplakia of colon in an immunocompromised patient due to steroids and azathioprin for the treatment of recurrent oral ulcers of unknown aetiology and pemphigous vulgaris

Malakoplakia of colon in an immunocompromised patient due to steroids and azathioprin for the treatment of recurrent oral ulcers of unknown aetiology and pemphigous vulgaris

OP0183 Rebamipide: A potential useful therapeutic addition in the treatment of recurrent oral ulcers in behÇet’s disease

BackgroundRecurrent oral ulceration is one of the hallmarks of Behçet’s disease (BD). To date, various clinical manifestations, including aphthous ulcers are treated with limited success. Rebamipide is an anti-ulcer, gastro-protective...